The Clinical Value of Circulating Transcript Analysis (NETest) during Follow-Up of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors

#2273

Introduction: Follow-up after resection of pancreatic neuroendocrine tumors (pNET) is designed to detect recurrence early, as incidence is reported up to 48%.

Aim(s): We investigated the role of a PCR-based blood-test, the NETest, to detect recurrence during postoperative follow-up.

Materials and methods: Patients were included who have undergone curative resection of G1/G2 pNET, without distant metastases or hereditary syndromes. They were divided into three groups: R0 resection with no signs of recurrence (R0NR, n=11), R0 resection with recurrence on imaging (R0R, n=12) and R1 resection without recurrence (R1NR, n=12). NETest scores were compared to other biomarkers (chromogranin A (CgA)) and known clinical variables (grade, lymph node metastases (LN+), size) previously associated with recurrence. Eleven healthy controls were included.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Genc C, Jilesen A, Nieveen van Dijkum E, Klümpen H, Van Eijck C,

Keywords: neuroendocrine, pancreas, recurrence, biomarker, NETest, postoperative follow-up,

To read the full abstract, please log into your ENETS Member account.